BR112013030067A2 - "conjugado polipeptídico, composição farmacêutica compreendendo o referido conjugado e uso do mesmo" - Google Patents
"conjugado polipeptídico, composição farmacêutica compreendendo o referido conjugado e uso do mesmo"Info
- Publication number
- BR112013030067A2 BR112013030067A2 BR112013030067A BR112013030067A BR112013030067A2 BR 112013030067 A2 BR112013030067 A2 BR 112013030067A2 BR 112013030067 A BR112013030067 A BR 112013030067A BR 112013030067 A BR112013030067 A BR 112013030067A BR 112013030067 A2 BR112013030067 A2 BR 112013030067A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- diabetes
- conjugate
- polypeptide
- syndrome
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 abstract 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010033307 Overweight Diseases 0.000 abstract 1
- 206010049416 Short-bowel syndrome Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000001352 cholecystitis Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 208000004104 gestational diabetes Diseases 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 229920003169 water-soluble polymer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161489781P | 2011-05-25 | 2011-05-25 | |
| PCT/US2012/039431 WO2012162542A1 (en) | 2011-05-25 | 2012-05-24 | Amylin peptides and derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013030067A2 true BR112013030067A2 (pt) | 2016-11-29 |
Family
ID=47217749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013030067A BR112013030067A2 (pt) | 2011-05-25 | 2012-05-24 | "conjugado polipeptídico, composição farmacêutica compreendendo o referido conjugado e uso do mesmo" |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20140221287A1 (enExample) |
| EP (1) | EP2714067A1 (enExample) |
| JP (1) | JP2014516049A (enExample) |
| KR (1) | KR20140045433A (enExample) |
| CN (1) | CN103826655A (enExample) |
| BR (1) | BR112013030067A2 (enExample) |
| CA (1) | CA2837104A1 (enExample) |
| CL (1) | CL2013003377A1 (enExample) |
| CO (1) | CO6821894A2 (enExample) |
| EA (1) | EA201391763A1 (enExample) |
| IL (1) | IL229449A0 (enExample) |
| MX (1) | MX2013013802A (enExample) |
| PH (1) | PH12013502385A1 (enExample) |
| SG (1) | SG194998A1 (enExample) |
| TN (1) | TN2013000491A1 (enExample) |
| WO (1) | WO2012162542A1 (enExample) |
| ZA (1) | ZA201309679B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2068909B1 (en) | 2007-03-30 | 2012-04-25 | Ambrx, Inc. | Modified fgf-21 polypeptides and their uses |
| TW201625671A (zh) * | 2014-09-04 | 2016-07-16 | 諾佛 儂迪克股份有限公司 | 新穎澱粉素及降鈣素受體促效劑 |
| CN104327162A (zh) * | 2014-09-28 | 2015-02-04 | 苏州普罗达生物科技有限公司 | 一种胰岛素淀粉样多肽抑制剂及其制备方法、应用 |
| KR102854572B1 (ko) | 2014-10-24 | 2025-09-02 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 fgf-21 폴리펩티드 및 그의 용도 |
| US11028137B2 (en) | 2017-02-01 | 2021-06-08 | The Research Foundation For The State University Of New York | Mutant islet amyloid polypeptides with improved solubility and methods for using the same |
| WO2019207427A2 (en) * | 2018-04-25 | 2019-10-31 | Janssen Pharmaceutica Nv | Thioether cyclic peptide amylin receptor modulators |
| JP7652422B2 (ja) | 2018-11-02 | 2025-03-27 | ベイジン ブイディージェイバイオ カンパニー， リミテッド | 修飾されたｃｔｌａ４およびその使用方法 |
| CN110467666A (zh) * | 2019-09-17 | 2019-11-19 | 湖北强耀生物科技有限公司 | 一种新型胰岛淀粉样多肽的合成方法 |
| TW202400632A (zh) | 2021-03-03 | 2024-01-01 | 美商美國禮來大藥廠 | 長效澱粉素受體促效劑及其用途 |
| IL312672A (en) * | 2021-11-10 | 2024-07-01 | I2O Therapeutics Inc | Ionic liquid compositions |
| CN119278209A (zh) | 2022-05-27 | 2025-01-07 | 杭州先为达生物科技股份有限公司 | 人胰淀素类似物、其衍生物及用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2233497A3 (en) * | 2004-02-11 | 2011-01-12 | Amylin Pharmaceuticals, Inc. | Amylin family peptides and methods for making and using them |
| WO2006086769A2 (en) * | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
| EP1996617A2 (en) * | 2006-03-15 | 2008-12-03 | Novo Nordisk A/S | Amylin derivatives |
| EP2036923A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| EP2036539A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
| ES2632504T3 (es) * | 2007-11-20 | 2017-09-13 | Ambrx, Inc. | Polipéptidos de insulina modificados y sus usos |
-
2012
- 2012-05-24 SG SG2013084892A patent/SG194998A1/en unknown
- 2012-05-24 EA EA201391763A patent/EA201391763A1/ru unknown
- 2012-05-24 CN CN201280036795.0A patent/CN103826655A/zh active Pending
- 2012-05-24 BR BR112013030067A patent/BR112013030067A2/pt not_active IP Right Cessation
- 2012-05-24 PH PH1/2013/502385A patent/PH12013502385A1/en unknown
- 2012-05-24 KR KR1020137033991A patent/KR20140045433A/ko not_active Withdrawn
- 2012-05-24 US US14/119,574 patent/US20140221287A1/en not_active Abandoned
- 2012-05-24 EP EP12789229.7A patent/EP2714067A1/en not_active Withdrawn
- 2012-05-24 JP JP2014512115A patent/JP2014516049A/ja not_active Withdrawn
- 2012-05-24 CA CA2837104A patent/CA2837104A1/en not_active Abandoned
- 2012-05-24 MX MX2013013802A patent/MX2013013802A/es not_active Application Discontinuation
- 2012-05-24 WO PCT/US2012/039431 patent/WO2012162542A1/en not_active Ceased
-
2013
- 2013-11-14 IL IL229449A patent/IL229449A0/en unknown
- 2013-11-22 TN TNP2013000491A patent/TN2013000491A1/fr unknown
- 2013-11-25 CL CL2013003377A patent/CL2013003377A1/es unknown
- 2013-12-19 CO CO13296527A patent/CO6821894A2/es not_active Application Discontinuation
- 2013-12-20 ZA ZA2013/09679A patent/ZA201309679B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL229449A0 (en) | 2014-01-30 |
| WO2012162542A1 (en) | 2012-11-29 |
| KR20140045433A (ko) | 2014-04-16 |
| CA2837104A1 (en) | 2012-11-29 |
| MX2013013802A (es) | 2014-04-25 |
| PH12013502385A1 (en) | 2014-01-13 |
| US20140221287A1 (en) | 2014-08-07 |
| EA201391763A1 (ru) | 2014-04-30 |
| NZ618526A (en) | 2015-09-25 |
| CO6821894A2 (es) | 2013-12-31 |
| ZA201309679B (en) | 2016-10-26 |
| CL2013003377A1 (es) | 2014-07-04 |
| CN103826655A (zh) | 2014-05-28 |
| SG194998A1 (en) | 2013-12-30 |
| EP2714067A1 (en) | 2014-04-09 |
| TN2013000491A1 (en) | 2015-03-30 |
| JP2014516049A (ja) | 2014-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013030067A2 (pt) | "conjugado polipeptídico, composição farmacêutica compreendendo o referido conjugado e uso do mesmo" | |
| WO2013059336A8 (en) | Amylin-calcitonin chimeric peptides conjugated to duration enchancing moieties | |
| CL2007002347A1 (es) | Compuestos derivados de fenilo, piridina y quinolina; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de diabetes mellitus, trastornos en la tolerancia de la glucosa, obesidad, enfermedad de crohn, enferm | |
| JP2014511863A5 (enExample) | ||
| RU2739209C2 (ru) | Новые производные оксинтомодулина и содержащая их фармацевтическая композиция для лечения ожирения | |
| WO2012051567A3 (en) | Obesity-related genes and their proteins and uses thereof | |
| MX2011007544A (es) | Derivados de factor de crecimiento de fibroblastos 21 (fgf21) con ligante de albumina a-b-c-d-e- y su uso. | |
| BR112015004734A2 (pt) | proteínas de fusão para tratar uma síndrome metabólica | |
| BR112012027759A2 (pt) | Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso | |
| EP1992645A4 (en) | NOVEL HYALURONIC ACID WITH LOW MOLECULAR WEIGHT AND / OR SALT THEREOF, AND COSMETIC PREPARATION, PHARMACEUTICAL COMPOSITION AND EACH FOOD COMPOSITION USING THE SAME | |
| EA200870575A1 (ru) | Композиции и способы лечения застойной сердечной недостаточности | |
| BR112013007442A2 (pt) | polipeptídeos construídos tendo duração de ação realçada | |
| BR112013029409A2 (pt) | "produto de peptídeo compreendendo tensoativo ligado de forma covalente a peptídeo, composição farmacêutica que o compreende, bem como uso de produto de peptídeo no tratamento de condição associada à resistência à insulina, doença cardiovascular e diabetes" | |
| BR112014018575A2 (pt) | polipetídeos de fator de diferenciação de crescimento 15 (gdf-15) | |
| EA200870365A1 (ru) | Эндотелин и агонисты рецепторов к эндотелину в лечении заболеваний обмена веществ | |
| WO2013009545A8 (en) | Engineered polypeptides having enhanced duration of action with reduced immunogenicity | |
| MX2009011359A (es) | Derivados de pirimidinona y sus metodos de uso. | |
| BR112015014510A2 (pt) | agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais | |
| BR112014012815A2 (pt) | derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença | |
| BR112013031033A2 (pt) | composição destinada ao tratamento de diabetes, compreendendo conjugado de insulina de ação prolongada e conjugado de peptídeo insulinotrópico de ação prolongada | |
| FI2981255T3 (fi) | Empagliflotsiinin terapeuttiset käytöt | |
| BR112018011002A2 (pt) | variantes de fgf21 | |
| WO2010053545A3 (en) | Apj receptor compounds | |
| JP2010031018A5 (enExample) | ||
| WO2009042922A3 (en) | Peptide-peptidase inhibitor conjugates and methods of making and using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |